Drugs / 11C-JNJ-63779586
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03089918 | May 2017 → Aug 2018 | Alzheimer disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-JNJ-63779586 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03089918 ↗ |
| Route | Intravenous | “Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.” NCT03089918 ↗ |